Generate Biomedicines priced an IPO that raised roughly $400 million to fund pivotal trials for its severe asthma program and further develop its programmable‑biology platform. Founded by Flagship Pioneering, Generate’s lead asset targets TSLP and the company positions its AI/ML protein design capabilities as a differentiator for less‑frequent dosing biologics. The offering closed with strong demand but shares dipped in the aftermarket, a mixed signal about investor appetite for platform‑driven biotechs. The financing provides material runway for pivotal testing and highlights continued public-market interest in AI‑augmented drug design despite broader biotech volatility. Reporting sources include MedCity News and contemporaneous IPO filings and coverage.